Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

Against the backdrop of Music City’s biggest weekend, leading experts and frontline clinicians will gather in downtown Nashville, Tennessee, for one of dermatology’s most impactful educational events ...

Kymera Therapeutics (KYMR) announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, ...

Ninety-five percent (95%) of U.S. dermatology providers surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a ...

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those ...

In this second part of a video series, Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland ...